Nigella Sativa Supplementation in Hyperlipidemia Treatment

Launched by ISTANBUL BILGI UNIVERSITY · Mar 21, 2025

Keywords

ClinConnect Summary

This research, which is a randomized controlled intervention study, was conducted between June 2023 and February 2024 with adult individuals with a BMI\>25 kg/m2 who applied to the Cardiology Polyclinic of Karamürsel State Hospital and were referred to a nutrition and diet specialist after being diagnosed with hyperlipidemia according to AHA criteria by the physician.

Sample Selection and Randomization The sample size of the study was calculated using the G-Power 3.1.9 analysis program with a medium effect size (d=0.60), 90% power, α: 0.05 and 1-β: 0.95, with a minimum of 32 people in each...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults individuals who were diagnosed hyperlipidemia
• • Individuals suitable for taking Nigella satvia supplement
• • Individuals BMI\>25 kg/m2
• Exclusion Criteria:
• • Chronic liver disease,
• • Chronic kidney disease,
• • Heart failure, infarction or cerebrovascular disease,
• • Pregnant and breastfeeding women,
• • Severe psychiatric disorders,
• • Oncological diseases,
• • Individuals using medications that could interact with black seed oil (anticoagulant, antihypertensive, etc.)
• • Individuals using antilipidemic or anticholesterolemic medications
• • Individuals did not do heavy exercise
• • Individuals using any nutritional supplement
• • Individuals have a known history of allergy
• • Individuals did not consume alcohol regularly
• • Individuals with special dietary needs

Trial Officials